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breakdown of individual items, making it difficult to replicate the analysis for other settings. The sources of costs were presented, with most estimates based on a recent health technology assessment (National Board for Health, 2007) , but few details of resource use were reported. The price year and time horizon were stated and the discount rate for longterm costs was appropriately applied. All the cost categories, such as treatment and vaccine price, appear to have been tested in the sensitivity analyses.
Analysis and results:
The analytic approach was appropriate and the model structure was presented in a supplementary file. A synthesis of costs and benefits was performed, but only the incremental results were reported. The uncertainty was partly investigated in a univariate sensitivity analysis, but no probabilistic sensitivity analysis was performed, because of the excessive computer processing time needed. Several alternative vaccination scenarios were considered and comparisons with other studies were made. The authors acknowledged several limitations of their study, such as the exclusion of transmission between homosexual and heterosexual people, a reduction in sexual contacts as individuals aged, and no reintroduction of HPV once treated.
Concluding remarks:
The methods were valid and, despite some limitations in the reporting of the data sources and the results, the authors' conclusions appear to be appropriate.
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